Microbot Medical Inc (MBOT)vsResMed Inc (RMD)
MBOT
Microbot Medical Inc
$1.84
-6.12%
HEALTHCARE · Cap: $132.99M
RMD
ResMed Inc
$196.04
+0.89%
HEALTHCARE · Cap: $28.25B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 5273985% more annual revenue ($5.54B vs $105,000). RMD leads profitability with a 27.4% profit margin vs 0.0%. MBOT appears more attractively valued with a PEG of 0.70. RMD earns a higher WallStSmart Score of 73/100 (B).
MBOT
Avoid34
out of 100
Grade: F
RMD
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MBOT.
Margin of Safety
-26.9%
Fair Value
$204.63
Current Price
$196.04
$8.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 35.3%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : MBOT
The strongest argument for MBOT centers on Debt/Equity, Altman Z-Score, PEG Ratio. PEG of 0.70 suggests the stock is reasonably priced for its growth.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.
Bear Case : MBOT
The primary concerns for MBOT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Key Dynamics to Monitor
MBOT profiles as a value stock while RMD is a mature play — different risk/reward profiles.
MBOT carries more volatility with a beta of 1.06 — expect wider price swings.
RMD is growing revenue faster at 10.8% — sustainability is the question.
RMD generates stronger free cash flow (520M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (73/100 vs 34/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Microbot Medical Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Microbot Medical Inc., a preclinical medical device company, researches, designs and develops micro-robotic-assisted medical technologies targeting the minimally invasive surgery space. The company is headquartered in Hingham, Massachusetts.
Visit Website →ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?